1,500
Participants
Start Date
December 15, 2024
Primary Completion Date
December 31, 2040
Study Completion Date
December 31, 2043
No Intervention (subjects were previously treated with Equecabtagene Autoleucel Injection) )
This study is observational study and all participants will be obsreved with no intervention.
NOT_YET_RECRUITING
Peking University First Hospital, Beijing
NOT_YET_RECRUITING
People's Hospital of Peking Universit, Beijing
RECRUITING
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin
RECRUITING
Tianjin Medical University General Hospital, Tianjin
NOT_YET_RECRUITING
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
NOT_YET_RECRUITING
Henan Cancer Hospital Affilated Cancer Hospital of Zhengzhou University, Zhengzhou
Nanjing IASO Biotechnology Co., Ltd.
INDUSTRY